Institut Bergonié

This study is testing a combination of three treatments—an immunotherapy drug (atezolizumab), a new immune-stimulating drug (BDB001), and targeted radiation—to see if they can better control advanced solid tumors. It is enrolling 247 adults with specific advanced cancers, includi…

This study is testing whether a new digital care system can improve quality of life for older adults who have cancer along with other health conditions. It will involve 720 patients aged 70+ with breast, lung, colorectal, or prostate cancer across eight hospitals in France. The m…

This study is testing if adding a tumor-freezing procedure (cryoablation) to standard drug therapy helps people with advanced lung cancer live longer. It will enroll 214 patients who will be randomly assigned to receive either the standard drugs alone or the drugs plus the freezi…

This study is testing whether regularly checking for cancer DNA in the blood (a 'liquid biopsy') can help doctors better manage treatment for advanced colorectal or lung cancer. Patients will have their tumor's genetics analyzed, and a team of experts will recommend a treatment p…

This study is testing whether adding a new drug called berzosertib to standard chemotherapy (gemcitabine) can better control advanced leiomyosarcoma, a type of soft-tissue cancer. It will involve 72 adults whose cancer has progressed despite prior treatments. The main goal is to …

This trial is testing if giving six cycles of chemotherapy before surgery works better than the standard three cycles for patients with high-risk, non-metastatic soft-tissue sarcoma. The goal is to see if the extra treatment can better prevent the cancer from spreading to other p…

This study is testing if a newer drug called darolutamide, when given for 6 months alongside standard radiation therapy, can effectively control prostate cancer. It is being compared to the current standard treatment, which combines radiation with a different type of hormone ther…

This trial is testing whether combining two existing cancer drugs—pembrolizumab and cabozantinib—can help control advanced sarcomas that have stopped responding to standard treatments. It will enroll about 119 adults with specific types of advanced sarcoma. The main goal is to se…

This study is testing whether high-intensity focused ultrasound (HIFU) can destroy small breast tumors before surgery. It will involve 15 patients with early-stage breast cancer. The goal is to see if this non-invasive technique can effectively remove tumor cells, potentially lea…

This study is testing whether artificial intelligence (AI) can help doctors better classify and predict the future behavior of certain uterine muscle tumors. Researchers will use AI to analyze microscope images of tumor tissue from about 400 patients. The goal is to create a comp…

This study is creating a large database of breast cancer patients treated at a single center since the 1990s. It aims to track long-term survival, understand treatment practices, and identify factors that predict outcomes. The research does not test new treatments but collects in…

This study aims to better understand the cancer risks for people born with a change in their PTEN gene, a condition linked to Cowden syndrome. Researchers will follow 430 participants in France over time, collecting their health information through questionnaires. The goal is to …

This study is creating a large national database to collect health information from 150,000 people in France diagnosed with sarcoma, a type of cancer. The goal is to gather data on how patients are treated and what their outcomes are over time. This information will help research…

This study aims to understand how the amount of radiation delivered by a prostate cancer treatment affects patient outcomes and side effects. Researchers will observe 50 patients with advanced prostate cancer who are receiving a standard treatment called 177Lu-PSMA-617. They will…

This study is testing whether a simple blood test can predict if breast cancer will return after initial treatment. It will follow 180 patients whose cancer did not completely disappear after chemotherapy, taking blood samples every 6 months for 5 years. The goal is to see if tin…

This study aims to validate a genetic test called CINSARC to see if it can predict how well patients with soft-tissue sarcoma will respond to chemotherapy and their long-term outcomes. It will observe about 205 adults with non-metastatic sarcoma who are scheduled to receive chemo…

This study aims to analyze the genetic makeup of advanced cancers to find specific weaknesses that drugs can target. Researchers will test tumor samples from 10,000 adults with solid tumors or blood cancers. The goal is to use this detailed genetic information to match patients w…